Evan Lipson, MD
"To me, research means creating new tools to help improve the lives of people affected by cancer."
Dr. Lipson is a cutaneous oncology and clinical immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center.
Dr. Lipson's primary research interest is in early-phase clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson is a principal or co-investigator on multiple trials, involving partners from both industry and academia, which focus on the clinical development of antibodies that block the PD-1/PD-L1 pathway. Dr. Lipson’s publications include the first description of successful PD-1 re-induction therapy (Clin Can Res 2013), and the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer (JCO 2014, NEJM 2016).
Dr. Lipson is an MRA-funded investigator.